Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre